Acumen Pharmaceuticals Reports Third Quarter 2022 Financial Results and Business Highlights
14 nov. 2022 16h01 HE
|
Acumen Pharmaceuticals, Inc.
INTERCEPT-AD, a Phase 1 clinical trial of ACU193 in patients with early Alzheimer’s disease continues to progress Acumen anticipates completing enrollment in the first quarter of 2023 and reporting...
Acumen Pharmaceuticals to Participate in the Stifel Healthcare Conference
09 nov. 2022 16h01 HE
|
Acumen Pharmaceuticals, Inc.
CHARLOTTESVILLE, Va. and CARMEL, Ind., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company focused on the development of novel...
Acumen Pharmaceuticals to Report Third Quarter 2022 Financial Results on Nov. 14, 2022
07 nov. 2022 16h01 HE
|
Acumen Pharmaceuticals, Inc.
CHARLOTTESVILLE, Va. and CARMEL, Ind., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company focused on the development of novel...
Acumen Publishes Phase 1 Trial Design and Clinical Development Plan for ACU193, an Anti-Amyloid Beta Oligomer Antibody for Alzheimer’s Disease
01 nov. 2022 08h00 HE
|
Acumen Pharmaceuticals, Inc.
CHARLOTTESVILLE, Va. and CARMEL, Ind., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) today announced that it published its development rationale and clinical...
Acumen’s ACU193, an Anti-Amyloid Beta Oligomer Antibody, Granted FDA Fast Track Designation for Alzheimer's Disease
24 oct. 2022 08h00 HE
|
Acumen Pharmaceuticals, Inc.
CHARLOTTESVILLE, Va. and CARMEL, Ind., Oct. 24, 2022 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) today announced that ACU193, the first clinical-stage monoclonal antibody that...
Acumen Pharmaceuticals Reports Financial Results for Second Quarter 2022 and Business Highlights
15 août 2022 16h05 HE
|
Acumen Pharmaceuticals, Inc.
Topline results expected in the first half of 2023 from INTERCEPT-AD, a multi-center, randomized, double-blind, placebo-controlled, single- and multiple-ascending dose Phase 1 clinical trial of ACU193...
Acumen Pharmaceuticals to Report Second Quarter 2022 Financial Results on August 15, 2022
08 août 2022 16h15 HE
|
Acumen Pharmaceuticals, Inc.
CHARLOTTESVILLE, Va. and CARMEL, Ind., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical stage biopharmaceutical company focused on the development of novel...
Acumen presents poster describing method to standardize amyloid beta oligomer assays supporting therapeutic development for early Alzheimer’s disease
01 août 2022 10h30 HE
|
Acumen Pharmaceuticals, Inc.
CHARLOTTESVILLE, Va. and CARMEL, Ind., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Scientists at Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) have developed a synthetic model to potentially standardize the...
Acumen Pharmaceuticals to Participate in Upcoming Investor and Scientific Conferences
26 juil. 2022 16h15 HE
|
Acumen Pharmaceuticals, Inc.
CHARLOTTESVILLE, Va. and CARMEL, Ind., July 26, 2022 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical stage biopharmaceutical company focused on the development of novel...
Acumen Pharmaceuticals Reports Financial Results for First Quarter 2022 and Business Highlights
16 mai 2022 16h05 HE
|
Acumen Pharmaceuticals, Inc.
Topline results expected in the first half of 2023 from INTERCEPT-AD, a multi-center, randomized, double-blind, placebo-controlled, single- and multiple-ascending dose Phase 1 clinical trial of ACU193...